New updates have been reported about Ro (PC:ROHLC)
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ro, a leader in direct-to-patient healthcare, has published a groundbreaking study demonstrating the effectiveness of semaglutide treatment via telehealth. The peer-reviewed research, featured in the journal Obesity, reveals that patients using Ro’s platform experienced an average weight loss of 16.6% over 68 weeks. This study is the first to assess both the long-term weight loss and safety outcomes of semaglutide treatment delivered through telehealth, aligning with results from traditional clinical trials.
The study involved 655 patients, predominantly women, with a median baseline BMI of 32.3 kg/m². Notably, 95.4% of participants achieved at least a 5% reduction in body weight, with 82% losing 10% or more. Ro’s comprehensive obesity care offering, which includes ongoing clinician support and personalized medication adjustments, played a crucial role in these outcomes. The research highlights telehealth as a vital tool for large-scale weight management, reinforcing Ro’s commitment to providing effective and safe healthcare solutions. No new safety concerns were identified, with nausea and constipation being the most common side effects. This study underscores Ro’s innovative approach to healthcare, leveraging technology to deliver high-quality care and achieve clinical trial-level results.